140 related articles for article (PubMed ID: 34923175)
1. Hepatic TM6SF2 Is Required for Lipidation of VLDL in a Pre-Golgi Compartment in Mice and Rats.
Luo F; Smagris E; Martin SA; Vale G; McDonald JG; Fletcher JA; Burgess SC; Hobbs HH; Cohen JC
Cell Mol Gastroenterol Hepatol; 2022; 13(3):879-899. PubMed ID: 34923175
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins.
Smagris E; Gilyard S; BasuRay S; Cohen JC; Hobbs HH
J Biol Chem; 2016 May; 291(20):10659-76. PubMed ID: 27013658
[TBL] [Abstract][Full Text] [Related]
3. Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.
Ehrhardt N; Doche ME; Chen S; Mao HZ; Walsh MT; Bedoya C; Guindi M; Xiong W; Ignatius Irudayam J; Iqbal J; Fuchs S; French SW; Mahmood Hussain M; Arditi M; Arumugaswami V; Péterfy M
Hum Mol Genet; 2017 Jul; 26(14):2719-2731. PubMed ID: 28449094
[TBL] [Abstract][Full Text] [Related]
4. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content.
Mahdessian H; Taxiarchis A; Popov S; Silveira A; Franco-Cereceda A; Hamsten A; Eriksson P; van't Hooft F
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8913-8. PubMed ID: 24927523
[TBL] [Abstract][Full Text] [Related]
5. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
Borén J; Adiels M; Björnson E; Matikainen N; Söderlund S; Rämö J; Ståhlman M; Ripatti P; Ripatti S; Palotie A; Mancina RM; Hakkarainen A; Romeo S; Packard CJ; Taskinen MR
JCI Insight; 2020 Dec; 5(24):. PubMed ID: 33170809
[TBL] [Abstract][Full Text] [Related]
6. Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism.
Liu J; Ginsberg HN; Reyes-Soffer G
Curr Opin Lipidol; 2024 Jun; 35(3):157-161. PubMed ID: 38465912
[TBL] [Abstract][Full Text] [Related]
7. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH
Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759
[TBL] [Abstract][Full Text] [Related]
8. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
Luukkonen PK; Zhou Y; Nidhina Haridas PA; Dwivedi OP; Hyötyläinen T; Ali A; Juuti A; Leivonen M; Tukiainen T; Ahonen L; Scott E; Palmer JM; Arola J; Orho-Melander M; Vikman P; Anstee QM; Olkkonen VM; Orešič M; Groop L; Yki-Järvinen H
J Hepatol; 2017 Jul; 67(1):128-136. PubMed ID: 28235613
[TBL] [Abstract][Full Text] [Related]
9. TM6SF2 Determines Both the Degree of Lipidation and the Number of VLDL Particles Secreted by the Liver.
Reyes-Soffer G; Liu J; Thomas T; Matveyenko A; Seid H; Ramakrishnan R; Holleran S; Zaghloul N; Sztalryd-Woodle C; Pollin T; Ginsberg HN
medRxiv; 2023 Jun; ():. PubMed ID: 37425717
[TBL] [Abstract][Full Text] [Related]
10. TM6SF2 rs58542926 impacts lipid processing in liver and small intestine.
O'Hare EA; Yang R; Yerges-Armstrong LM; Sreenivasan U; McFarland R; Leitch CC; Wilson MH; Narina S; Gorden A; Ryan KA; Shuldiner AR; Farber SA; Wood GC; Still CD; Gerhard GS; Robishaw JD; Sztalryd C; Zaghloul NA
Hepatology; 2017 May; 65(5):1526-1542. PubMed ID: 28027591
[TBL] [Abstract][Full Text] [Related]
11. S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease.
Martínez-Uña M; Varela-Rey M; Mestre D; Fernández-Ares L; Fresnedo O; Fernandez-Ramos D; Gutiérrez-de Juan V; Martin-Guerrero I; García-Orad A; Luka Z; Wagner C; Lu SC; García-Monzón C; Finnell RH; Aurrekoetxea I; Buqué X; Martínez-Chantar ML; Mato JM; Aspichueta P
J Hepatol; 2015 Mar; 62(3):673-81. PubMed ID: 25457203
[TBL] [Abstract][Full Text] [Related]
12. Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease.
Li BT; Sun M; Li YF; Wang JQ; Zhou ZM; Song BL; Luo J
PLoS Genet; 2020 Aug; 16(8):e1008955. PubMed ID: 32776921
[TBL] [Abstract][Full Text] [Related]
13. Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development.
Yang M; Liu Q; Huang T; Tan W; Qu L; Chen T; Pan H; Chen L; Liu J; Wong CW; Lu WW; Guan M
Theranostics; 2020; 10(24):10874-10891. PubMed ID: 33042259
[No Abstract] [Full Text] [Related]
14. Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly.
Hesse D; Radloff K; Jaschke A; Lagerpusch M; Chung B; Tailleux A; Staels B; Schürmann A
J Lipid Res; 2014 Jan; 55(1):41-52. PubMed ID: 24186947
[TBL] [Abstract][Full Text] [Related]
15. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.
Kozlitina J; Smagris E; Stender S; Nordestgaard BG; Zhou HH; Tybjærg-Hansen A; Vogt TF; Hobbs HH; Cohen JC
Nat Genet; 2014 Apr; 46(4):352-6. PubMed ID: 24531328
[TBL] [Abstract][Full Text] [Related]
16. Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice.
Fan Y; Lu H; Guo Y; Zhu T; Garcia-Barrio MT; Jiang Z; Willer CJ; Zhang J; Chen YE
Gastroenterology; 2016 May; 150(5):1208-1218. PubMed ID: 26774178
[TBL] [Abstract][Full Text] [Related]
17. [Construction of transmembrane 6 superfamily member 2 E167K gene knock-in mouse model by using CRISPR/Cas9 technology].
Sun BK; Liu SS; Zhang J; Xuan SY; Xin YN
Zhonghua Gan Zang Bing Za Zhi; 2020 Jul; 28(7):591-596. PubMed ID: 32791795
[No Abstract] [Full Text] [Related]
18. TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes.
Boyer A; Park SB; de Boer YS; Li Q; Liang TJ
Gastroenterology; 2018 Dec; 155(6):1923-1935.e8. PubMed ID: 30144428
[TBL] [Abstract][Full Text] [Related]
19. FITM2 deficiency results in ER lipid accumulation, ER stress, reduced apolipoprotein B lipidation, and VLDL triglyceride secretion
Wang H; Nikain C; Amengual J; La Forest M; Yu Y; Wang MC; Watts R; Lehner R; Qiu Y; Cai M; Kurland IJ; Goldberg IJ; Rajan S; Hussain MM; Brodsky JL; Fisher EA
bioRxiv; 2023 Dec; ():. PubMed ID: 38106013
[TBL] [Abstract][Full Text] [Related]
20. Regulation of hepatic secretion of very low density lipoprotein by dietary cholesterol.
Fungwe TV; Cagen L; Wilcox HG; Heimberg M
J Lipid Res; 1992 Feb; 33(2):179-91. PubMed ID: 1569371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
